ATE366568T1 - Aerosolformulierungen von salmeterol xinafoate - Google Patents

Aerosolformulierungen von salmeterol xinafoate

Info

Publication number: ATE366568T1
Authority: AT; Austria
Prior art keywords: formulations; salmeterol xinafoate; xinafoate; salmeterol; aerosol formulations
Prior art date: 1998-04-24

Application number

AT99920757T

Other languages

English (en)

Inventor

Simon Cooper

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-24

Filing date

1999-04-23

Publication date

2007-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10830947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366568(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-04-23 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE366568T1 publication Critical patent/ATE366568T1/de

Links

GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
239000000443 aerosol Substances 0.000 title abstract 2
229960005018 salmeterol xinafoate Drugs 0.000 title abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 abstract 2
238000009472 formulation Methods 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
SJJCQDRGABAVBB-UHFFFAOYSA-M 1-hydroxy-2-naphthoate Chemical compound C1=CC=C2C(O)=C(C([O-])=O)C=CC2=C1 SJJCQDRGABAVBB-UHFFFAOYSA-M 0.000 abstract 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 abstract 1
239000012530 fluid Substances 0.000 abstract 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
239000003380 propellant Substances 0.000 abstract 1
229960004017 salmeterol Drugs 0.000 abstract 1
229950000339 xinafoate Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Emergency Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99920757T 1998-04-24 1999-04-23 Aerosolformulierungen von salmeterol xinafoate ATE366568T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9808802.4A GB9808802D0 (en)	1998-04-24	1998-04-24	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
ATE366568T1 true ATE366568T1 (de)	2007-08-15

Family

ID=10830947

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99920757T ATE366568T1 (de)	1998-04-24	1999-04-23	Aerosolformulierungen von salmeterol xinafoate

Country Status (9)

Country	Link
US (1)	US6613307B1 (de)
EP (1)	EP1073429B1 (de)
JP (1)	JP2002512952A (de)
AT (1)	ATE366568T1 (de)
AU (1)	AU3821399A (de)
DE (1)	DE69936515T2 (de)
ES (1)	ES2289811T3 (de)
GB (1)	GB9808802D0 (de)
WO (1)	WO1999055319A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001037805A1 (en) *	1999-11-23	2001-05-31	Glaxo Group Limited	Pharmaceutical formulations of salmeterol
AU2206801A (en) *	1999-12-24	2001-07-09	Alan Leslie Cripps	Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
AR030516A1 (es) *	2000-08-31	2003-08-20	Glaxo Group Ltd	Uso de una combinacion de salmeterol y fluticasona
US6551578B2 (en) *	2001-02-15	2003-04-22	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
US6544497B2 (en) *	2001-02-15	2003-04-08	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
US6485707B2 (en)	2001-02-15	2002-11-26	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
US6596262B2 (en) *	2001-02-15	2003-07-22	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
US6475468B2 (en) *	2001-02-15	2002-11-05	Aeropharm Technology Incorporated	Modulated release particles for aerosol delivery
GB0208742D0 (en) *	2002-04-17	2002-05-29	Bradford Particle Design Ltd	Particulate materials
US7582284B2 (en)	2002-04-17	2009-09-01	Nektar Therapeutics	Particulate materials
US6915966B2 (en) *	2003-01-29	2005-07-12	Specialty Minerals (Michigan) Inc.	Apparatus for the gunning of a refractory material and nozzles for same
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2007505136A (ja) *	2003-09-10	2007-03-08	マツプ・フアーマシユーテイカルズ・インコーポレーテツド	ジヒドロエルゴタミンを肺吸入により体循環に送達するためのエアゾール製剤
TWI341836B (en)	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087192A2 (en) *	2004-03-12	2005-09-22	Cipla Limited	Salmeterol inhalation formulations
CN1957397A (zh) *	2004-03-30	2007-05-02	先锋株式会社	声音识别装置和声音识别方法
US7968575B2 (en)	2004-05-05	2011-06-28	Renopharm Ltd.	Nitric oxide donors and uses thereof
US8134010B2 (en)	2004-05-05	2012-03-13	Renopharm Ltd.	Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
EP1753734A1 (de)	2004-05-05	2007-02-21	Renopharm Ltd.	Stickstoffmonoxidspender und anwendungen davon
US7498445B2 (en)	2004-05-05	2009-03-03	Renopharm Ltd.	Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
WO2006023460A2 (en)	2004-08-16	2006-03-02	Theravance, Inc.	COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
GB0418791D0 (en) *	2004-08-23	2004-09-22	Glaxo Group Ltd	Novel process
US7854397B2 (en) *	2005-01-21	2010-12-21	Specialty Minerals (Michigan) Inc.	Long throw shotcrete nozzle
WO2008097664A1 (en)	2007-02-11	2008-08-14	Map Pharmaceuticals, Inc.	Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20090048155A1 (en)	2007-08-15	2009-02-19	Endacea, Inc.	Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
BRPI0816278A2 (pt) *	2007-09-05	2015-09-22	Pfizer Ltd	forma sal
EP2393488B1 (de)	2009-02-06	2019-06-19	University Of Southern California	Therapeutische zusammensetzungen mit monoterpenen
KR101742252B1 (ko)	2009-07-15	2017-05-31	세라밴스 바이오파마 알앤디 아이피, 엘엘씨	비페닐 화합물의 결정질 유리 염기형
WO2011094208A2 (en)	2010-01-26	2011-08-04	Endacea, Inc.	Methods and pharmaceutical compositions for preventing and treating renal impairment
US8507734B2 (en)	2010-03-03	2013-08-13	Neonc Technologies Inc.	Pharmaceutical compositions comprising monoterpenes
EP2571486A4 (de) *	2010-05-20	2013-12-04	Sun Pharma Advanced Res Co Ltd	Trockenpulverinhalationszusammensetzung
US20160038600A1 (en)	2012-08-03	2016-02-11	Neonc Technologies Inc.	Pharmaceutical compositions comprising poh derivatives
EP3173080B1 (de)	2010-08-27	2019-12-11	Neonc Technologies Inc.	Pharmazeutische zusammensetzungen mit derivaten des perillaalkohols
WO2012032546A2 (en)	2010-09-08	2012-03-15	Cadila Healthcare Limited	Process for the preparation of salmeterol and its intermediates
CN105616391B (zh)	2010-12-17	2021-03-19	尼昂克技术公司	使用异紫苏醇的方法和装置
EP2968312B1 (de)	2013-03-15	2018-01-31	Verona Pharma PLC	Arzneimittelkombination
PL3231444T3 (pl)	2014-05-12	2020-05-18	Verona Pharma Plc	Nowe leczenie
WO2015199626A1 (en) *	2014-06-27	2015-12-30	World Medicine İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇	STABLE AEROSOL FORMULATIONS OF β2- ADRENERGIC AGONISTS
KR20170131405A (ko)	2015-02-12	2017-11-29	네온씨 테크놀로지스, 아이엔씨.	페릴릴 알코올 유도체를 포함하는 의약 조성물
DK3547836T3 (da)	2016-11-30	2024-11-18	Univ Southern California	Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
DK3749291T3 (da)	2018-02-08	2024-04-08	Univ Southern California	Fremgangsmåder til permeabilisering af blod-hjerne-barrieren

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3706598A (en) *	1970-07-15	1972-12-19	Cpc International Inc	Solid,glass-like starch hydrolysates having high densities
JPH05500229A (ja) *	1991-04-12	1993-01-21	東レ株式会社	固体ポリペプチド微粒子のエアロゾル製剤とその製造方法
NZ246046A (en) *	1991-12-12	1995-12-21	Glaxo Group Ltd	Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
US5653962A (en) *	1991-12-12	1997-08-05	Glaxo Group Limited	Aerosol formulations containing P134a and particulate medicaments
US5301664A (en) *	1992-03-06	1994-04-12	Sievers Robert E	Methods and apparatus for drug delivery using supercritical solutions
GB9313650D0 (en) *	1993-07-01	1993-08-18	Glaxo Group Ltd	Method and apparatus for the formation of particles
NZ293163A (en) *	1994-09-21	1998-09-24	Inhale Therapeutic Syst	Inhalation medicament disperser, aerosol from high pressure gas entrainment of fluidised powder drawn from receptacle feed tube
JP2860951B2 (ja) *	1995-01-12	1999-02-24	株式会社萩原技研	抗菌性ポリマー組成物
US5780014A (en) *	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
TR199701169T1 (xx) *	1995-04-14	1998-03-21	Glaxo Wellcome Inc.	Salmeterol i�in �l��lm�� doz inhaleri.
US5977010A (en) *	1995-06-15	1999-11-02	Engelhard Corporation	Shaped hydrogenation catalyst and processes for their preparation and use
GB9606677D0 (en) *	1996-03-29	1996-06-05	Glaxo Wellcome Inc	Process and device

1998
- 1998-04-24 GB GBGB9808802.4A patent/GB9808802D0/en not_active Ceased
1999
- 1999-04-23 WO PCT/EP1999/002748 patent/WO1999055319A1/en not_active Ceased
- 1999-04-23 US US09/646,872 patent/US6613307B1/en not_active Expired - Fee Related
- 1999-04-23 ES ES99920757T patent/ES2289811T3/es not_active Expired - Lifetime
- 1999-04-23 JP JP2000545518A patent/JP2002512952A/ja active Pending
- 1999-04-23 EP EP99920757A patent/EP1073429B1/de not_active Revoked
- 1999-04-23 AT AT99920757T patent/ATE366568T1/de not_active IP Right Cessation
- 1999-04-23 AU AU38213/99A patent/AU3821399A/en not_active Abandoned
- 1999-04-23 DE DE69936515T patent/DE69936515T2/de not_active Revoked

Also Published As

Publication number	Publication date
US6613307B1 (en)	2003-09-02
GB9808802D0 (en)	1998-06-24
DE69936515D1 (de)	2007-08-23
WO1999055319A1 (en)	1999-11-04
EP1073429B1 (de)	2007-07-11
DE69936515T2 (de)	2007-11-22
JP2002512952A (ja)	2002-05-08
EP1073429A1 (de)	2001-02-07
ES2289811T3 (es)	2008-02-01
AU3821399A (en)	1999-11-16

Legal Events

Date	Code	Title	Description
2008-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE366568T1 (de)	2007-08-15	Aerosolformulierungen von salmeterol xinafoate
BR9406995A (pt)	1996-09-10	Carboxilato de I-hidroxi-2-naftaleno (xinafoato) de 4- hidroxi- 1-[[[6-(4-fenilbutoxi)hexil]amino]metil]-1,3- benzenodimetanol (salmeterol) xinafoato de salmeterol e composição farmacêutica
TR200100144T2 (tr)	2001-06-21	Farmasötik aerosol formülasyonu
MY194689A (en)	2022-12-15	Compositions containing fluorine substituted olefins and method and system using same
ITBS960094A0 (it)	1996-11-29	Composizione per uso cosmetico farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico
DK0717617T3 (da)	2001-02-05	Mikropartikler indeholdende aktive bestanddele og gas
CL2004000889A1 (es)	2005-03-18	COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
IL165977A (en)	2010-12-30	Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
IL203923A (en)	2013-03-24	Benzamide compounds, pharmaceutical compositions comprising them, use thereof in the preparation of medicaments and as medicaments and processes for the preparation of such compounds
IL153997A0 (en)	2003-07-31	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0300894A3 (en)	2008-05-28	Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use
DK0556239T3 (da)	1995-11-06	Aerosol indeholdende medikamenter
MXPA03006538A (es)	2003-09-22	Nuevos derivados de urea, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.
HUP0301817A3 (en)	2011-10-28	Kahalalide compounds, process for preparing thereof, pharmaceutical compositions comprising them and their use
AR020391A1 (es)	2002-05-08	Formulaciones microencapsuladas, un procedimiento para su obtencion y empleo de dichas formulaciones.
MXPA03009984A (es)	2004-02-12	PREPARACION PARA LA REMOCIoN DE MATERIAL QUERATINOSO ANORMAL.
DK1474491T3 (da)	2006-05-29	Anvendelse af antiadhæsive emballagematerialer til emballering af kemikalier og levnedsmidler
DE60115997D1 (de)	2006-01-26	1,1- and 1,2-Disubstituierte Cyclopropane, Verfahren zu deren Herstellung und deren pharmazeutischen Zusammensetzungen
WO2002034240A3 (en)	2002-10-10	Delayed and sustained release formulations and method of use thereof
HUP0303195A3 (en)	2007-03-28	O-substituted 6-methyl-tramadol derivatives, process for their preparation and pharmaceutical compositions containing them
WO2002000191A3 (de)	2003-06-05	Bdellosomen
NO20023249D0 (no)	2002-07-04	Nye substituerte pyrazolo(4,3-e)ediazepiner, farmasöytiske preparater inneholdende disse, anvendelse som medisinske produkterog fremgangsmåter for fremstilling derav
HUP0303804A3 (en)	2005-09-28	Ligands of the avss6 integrin, process for their preparation, their use and pharmaceutical compositions containing them
EP1245562A4 (de)	2004-12-15	5-thia-"omega"-(substituiertes phenyl)-prostaglandin e alkohole, verfahren zur herstellung der alkohole und pharmzeutische zusammensetzungen, die diese als aktive inhaltsstoffe enthalten
ZA200300777B (en)	2003-09-18	Process for the preparation of peptide salts, their use and pharmaceutical preparations comprising the peptide salts.